Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Nippon Shinyaku’s DMD Treatment Approved in US
August 17, 2020
- AbbVie Japan Alters Company Rules for Same-Sex, Common-Law Marriages
August 17, 2020
- Fujifilm-Sponsored Avigan Trial to Complete Enrollment on Aug. 16
August 12, 2020
- Biosimilars Showing Accelerated Uptick in Japan, Doctor Fee Incentive as Tailwind
August 12, 2020
- 2 Employees Infected with Coronavirus: Pfizer Japan
August 12, 2020
- Denka to Launch Rapid Antigen Test Kit for COVID-19 on August 13
August 12, 2020
- Xarelto OD Tablets Approved, Specially Developed for Japan: Bayer
August 12, 2020
- Taiho Confirms COVID-19 Cluster at Its Training Center, 8 Test Positive
August 12, 2020
- Takeda Pairs with Novavax to Roll Out Coronavirus Vaccine in Japan, Wins 30 Billion Yen in Govt Funding
August 11, 2020
- Aducanumab Accepted for FDA Review with Priority Tag; Target Date Set for March 7
August 11, 2020
- Otsuka’s 1st Half Pharma Sales Rise 7.6% as 4 Global Brands Fare Well
August 11, 2020
- Mundipharma’s Sedative Agent Anerem Now Available in Japan
August 11, 2020
- Japan Ethical Drug Sales Up 0.9% in June: Crecon
August 11, 2020
- Daiichi Sankyo, AstraZeneca to Team Up for PI of Patritumab Deruxtecan/Tagrisso Combo in EGFR-Mutated NSCLC
August 11, 2020
- Japan’s Diabetic Market to Shrink after Peaking in FY2023: Yano Research
August 11, 2020
- Telomelysin-Keytruda Combo Trial to Begin in US for Head and Neck Cancer: Oncolys
August 11, 2020
- Axcelead Chief Says Small-Molecule Drug Targets More than Doubled in Last Few Years; IPO Eyed in 4-5 Years
August 7, 2020
- Sumitomo Dainippon Eyes 100 Billion Yen Sales from Frontier Biz: President
August 7, 2020
- Some Firms Curbing Supplies of Ethical Povidone-Iodine Products after Osaka COVID-19 Data
August 7, 2020
- Opdivo Eclipses Keytruda Again in July: Encise Drug Sales Ranking
August 7, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…